Share on StockTwits

Celgene (NASDAQ:CELG) reached a new 52-week high on Tuesday , Analyst RN reports. The company traded as high as $96.44 and last traded at $94.99, with a volume of 2,081,546 shares traded. The stock had previously closed at $95.02.

CELG has been the subject of a number of recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Celgene in a research note on Tuesday, August 26th. Separately, analysts at RBC Capital raised their price target on shares of Celgene from $95.00 to $100.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Monday, July 28th. They now have a $92.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $97.00.

The stock has a 50-day moving average of $88.71 and a 200-day moving average of $80.34. The company has a market cap of $75.889 billion and a price-to-earnings ratio of 54.92.

Celgene (NASDAQ:CELG) last released its earnings data on Thursday, July 24th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.89 by $0.01. The company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 17.1% on a year-over-year basis. On average, analysts predict that Celgene will post $3.67 earnings per share for the current fiscal year.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Receive News & Ratings for Celgene Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co and related companies with Analyst Ratings Network's FREE daily email newsletter.